arXiv:2607. 02768v1 Announce Type: cross Abstract: Pathologic complete response and tumor shrinkage measure whether breast cancer responds to neoadjuvant therapy, but not whether that response was structurally favorable, persistent, or hidden beneath volume loss.
arXiv:2607. 13984v1 Announce Type: cross Abstract: Longitudinal tumor measurements, dropout information, and genetic covariates provide complementary information about treatment response, but integrating these data sources within a single population modeling framework remains challenging.
arXiv:2608. 03145v1 Announce Type: new Abstract: Deep learning models can predict cancer recurrence from H&E stained slides, but the localized molecular states underlying these predictions remain largely obscured.
arXiv:2603. 01250v2 Announce Type: replace-cross Abstract: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a leading cause of cancer-related mortality.
arXiv:2606. 29977v1 Announce Type: cross Abstract: Objectives: To characterize residual false positives in prostate MRI detection, and to evaluate a lightweight post-hoc refinement head for case-level specificity.
arXiv:2606. 17115v1 Announce Type: cross Abstract: Foundation models (FMs) have emerged as powerful representation extractors for medical data, yet their generalizability to datasets under distribution shift remains underexplored.
arXiv:2607. 19137v1 Announce Type: cross Abstract: Inferring contrast enhancement from one pre-contrast breast MRI slice is underdetermined: post-contrast appearance contains physiological information that is not uniquely encoded in baseline anatomy.
Accurate prediction of patient-specific therapeutic response from pre-treatment transcriptomes is hindered by the scarcity of matched clinical response labels and post-treatment molecular profiles. Preclinical transfer-learning models can simulate drug-induced expression changes but are often hard to interpret and unstable, whereas knowledge-graph methods provide mechanistic context yet remain static and fail to capture drug-induced transcriptomic perturbation dynamics.
Objectives: To characterize residual false positives in prostate MRI detection, and to evaluate a lightweight post-hoc refinement head for case-level specificity. Materials and Methods: This retrospective study used PI-CAI (5-fold cross-validation) and Prostate158 (n=158; external).
arXiv:2607. 25497v1 Announce Type: cross Abstract: Pathology foundation models are approaching clinical deployment, yet remain vulnerable to systematic non-biological variation across centres.
Breast DCE-MRI AI is increasingly being explored for breast-level classification of no-lesion, benign, and malignant findings, beyond conventional lesion-centered diagnosis. Within this broader diagnostic scope, however, patient-specific background variability remains a major source of imaging confounding across classification tasks.
arXiv:2607. 29394v1 Announce Type: cross Abstract: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is essential for breast cancer management, but reliance on gadolinium-based contrast agents (GBCAs) restricts use in contraindicated populations, prolongs scan protocols, and presents environmental toxicity concerns.
arXiv:2606. 11876v1 Announce Type: cross Abstract: Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, producing a flickering sequence of faint detects and non-detects.